Geneseeq Technology Revenue and Competitors

Toronto, ON CAN

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Geneseeq Technology's estimated annual revenue is currently $6.8M per year.(i)
  • Geneseeq Technology's estimated revenue per employee is $155,000

Employee Data

  • Geneseeq Technology has 44 Employees.(i)
  • Geneseeq Technology grew their employee count by -8% last year.

Geneseeq Technology's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Deputy Director, Medical AffairsReveal Email/Phone
3
Associate DirectorReveal Email/Phone
4
Quality Assurance OfficerReveal Email/Phone
5
Scientific Affairs ManagerReveal Email/Phone
6
Manager Product DevelopmentReveal Email/Phone
7
Quality Assurance ManagerReveal Email/Phone
8
Senior ScientistReveal Email/Phone
9
Senior Project MangerReveal Email/Phone
10
Business Development AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.7M9-72%$39.4MN/A
#2
$0.9M11-83%$23.8MN/A
#3
$87.6M5656%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$7.8M50-68%N/AN/A
#6
$13.5M8730%N/AN/A
#7
$17.8M115-6%N/AN/A
#8
$0.9M11-39%N/AN/A
#9
$13.6M88-20%$86MN/A
#10
$20M129-12%N/AN/A
Add Company

What Is Geneseeq Technology?

Geneseeq is an industry leader in next-generation sequencing (NGS) fully committed to the research and clinical translation of NGS genetic sequencing in the field of personalized medicine. Geneseeq?s world-leading laboratories are accredited by College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA), and have sequenced over 250,000 cancer samples. Geneseeq currently owns all of Illumina?s sequencing platforms, including MiSeq, NextSeq500, HiSeq4000, HiSeq X10 and NovaSeq 6000.

keywords:N/A

N/A

Total Funding

44

Number of Employees

$6.8M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.7M4410%N/A
#2
N/A440%N/A
#3
$9.5M4413%N/A
#4
$9.5M4438%N/A
#5
$4.6M447%N/A